Wells Fargo lowered the firm’s price target on Agilon Health (AGL) to $4 from $8 and keeps an Overweight rating on the shares as the firm updates Managed Care estimates post-election. All estimates assume the expiration of enhanced exchange subsidies for 2026, Wells notes. The firm believes Medicare Advantage risk/reward improves with Republicans, although areas of concern still exist.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health price target lowered to $1.75 from $2.50 at Citi
- Agilon Health price target lowered to $2 from $7 at Stifel
- Agilon Health price target lowered to $2 from $6 at TD Cowen
- Agilon Health price target lowered to $2 from $5 at Barclays
- Agilon Health downgraded to Market Perform from Outperform at JMP Securities